SHR - A1811 Versus Chemotherapy for Platinum-resistant Recurrent Epithelial Ovarian Cancer

NCT06990503 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

300

Enrollment

OTHER

Sponsor class

Conditions

Ovarian Cancer

Interventions

DRUG: SHR-A1811
DRUG: Chemotherapy

Sponsor

Tongji Hospital